Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Operating Expenses: 2024-2025

Historic Other Operating Expenses for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $4.5 million.

  • Day One Biopharmaceuticals' Other Operating Expenses rose 181.76% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year change of. This contributed to the annual value of $5.3 million for FY2024, which is N/A change from last year.
  • Day One Biopharmaceuticals' Other Operating Expenses amounted to $4.5 million in Q3 2025, which was up 18.99% from $3.8 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Other Operating Expenses' 5-year high stood at $4.5 million during Q3 2025, with a 5-year trough of $707,000 in Q2 2024.
  • Over the past 2 years, Day One Biopharmaceuticals' median Other Operating Expenses value was $2.9 million (recorded in 2024), while the average stood at $2.7 million.
  • Data for Day One Biopharmaceuticals' Other Operating Expenses shows a peak YoY skyrocketed of 432.53% (in 2025) over the last 5 years.
  • Day One Biopharmaceuticals' Other Operating Expenses (Quarterly) stood at $3.0 million in 2024, then skyrocketed by 181.76% to $4.5 million in 2025.
  • Its Other Operating Expenses stands at $4.5 million for Q3 2025, versus $3.8 million for Q2 2025 and $2.9 million for Q1 2025.